| Literature DB >> 30229229 |
Makoto Hirao1, Jun Hashimoto2, Hideki Tsuboi3, Kosuke Ebina1, Akihide Nampei2, Takaaki Noguchi2, Shigeyoshi Tsuji2, Norihiro Nishimoto4,5, Hideki Yoshikawa1.
Abstract
BACKGROUND: Outcomes after total ankle arthroplasty (TAA) combined with additive techniques (augmentation of bone strength, control of soft-tissue balance, adjustment of the loading axis) for the treatment of rheumatoid arthritis were evaluated after intermediate to long-term follow-up. The influences of biologic treatment on the outcomes after TAA were also evaluated.Entities:
Year: 2017 PMID: 30229229 PMCID: PMC6133145 DOI: 10.2106/JBJS.OA.17.00033
Source DB: PubMed Journal: JB JS Open Access ISSN: 2472-7245
Fig. 1Panels A through C: Preoperative radiographs used for TAA planning. Panel A: Hip-to-calcaneus radiograph. The solid line shows the preoperative calcaneal tip and loading axis. The dashed line shows the ideal loading axis, which passes through the center of the distal plafond of the tibia. Panel B: Enlarged radiograph of the ankle area as shown in Panel A. Angle A (created by the lines connecting the center of the plafond and the calcaneal tip and the ideal loading axis) is defined as the angle that must be totally corrected for the adjustment of the weight-bearing line in the ankle joint. Panel C: Anteroposterior weight-bearing radiograph of the ankle in the standing position. Angle B (the angle between the distal tibial plafond and the perpendicular line to the long axis of the tibia) is defined as the correction angle to be achieved through tibial osteotomy.
Fig. 2Panels A and B: Intraoperative photographs showing devices used during the procedure. Panel A: The osteotomy guide for the tibia is similar to the tibial cutting guide that is used during total knee arthroplasty. This rigid guide is set up along the long axis of the tibial bone and is fixed with 2-mm Kirschner wires. The varus-valgus direction is adjustable in the coronal plane, and the inclination angle is adjustable in the sagittal plane. Alignment is checked with use of fluoroscopy. Panel B: The balancer is used after tibial and talar osteotomy. The space is spread to 18 mm (scale shown on the right side) because the minimum size of the spacer block in this prosthetic system is 17 mm. In this case, the gap of soft-tissue balance between the medial and lateral sides was 3° (scale shown on the left side) and a medial malleolar osteotomy was performed.
Fig. 3Panels A through C: Postoperative radiographic parameters. Panels A and B: The postoperative angular position of the tibial component is defined as the angle between the base plate of the tibial component and the long axis of the tibia on both anteroposterior (angle C) and lateral (angle D) radiographs. The postoperative tilting angle between the tibial and talar components is defined as the angle between the base plates of the tibial and talar components (angle E). Panel C: The tibiocalcaneal angle (TC angle) is measured on the subtalar view.
Fig. 4Panels A, B, and C: Anteroposterior (top) and subtalar (bottom) weight-bearing radiographs of a representative ankle that underwent subtalar-talonavicular joint arthrodesis prior to TAA. Panel A (top and bottom): Preoperative radiographs showing hindfoot valgus deformity and ankle joint destruction. The tibiocalcaneal angle was 24°. Panel B (top and bottom): Eight months after hindfoot-correction surgery, alignment was improved and the tibiocalcaneal angle had decreased to 5°. Panel C (top and bottom): Radiographs made 1 month after TAA for the treatment of residual ankle pain. Hydroxyapatite was also implanted into the distal part of the tibia.
Fig. 5Panels A through E: Radiographs of a representative ankle that underwent TAA with concomitant medial malleolar osteotomy. Hydroxyapatite was also implanted into the distal part of the tibia. Panel A: Preoperative weight-bearing anteroposterior radiograph of the ankle in the standing position. Panel B: Radiograph made immediately after TAA. Autologous bone chips were transplanted to the site of the opening-wedge osteotomy. Panel C: Radiograph made 1 year after TAA. Bone formation has progressed, and osseous fusion is almost completed at the osteotomy site. Panel D: Radiograph made 5 years after TAA. Osseous fusion has accelerated, and bone sclerosis is also observed. No implant loosening is seen. Panel E: Lateral radiograph of the ankle, made 5 years after TAA. No implant loosening is observed.
Fig. 6Panels A through D: Anteroposterior (top row) and lateral (bottom row) standing radiographs of a representative ankle that underwent revision TAA after subsidence of the talar component. Ankylosis of the subtalar joint was seen. Panel A (top and bottom): One month after primary TAA, coverage of talar component was not completely achieved, especially as seen on the lateral radiograph. Panel B (top and bottom): Two years after primary TAA, sinking of the talar component and a radiolucent area around tibial component were seen. Panel C (top and bottom): Radiographs made one month after revision TAA with use of a larger talar component with a long stem. Panel D (top and bottom): Radiographs made 8 years after revision TAA, showing no sinking of the talar component.
Demographic Characteristics*
| Age | 63.9 ± 8.7 (47 to 79) |
| Duration of disease | 19.3 ± 9.9 |
| Duration of follow-up | 7.1 ± 3.3 (3 to 14) |
| Female:male ratio | 36:8 |
| Height | 152.2 ± 8.4 (134 to 179) |
| Weight | 50.3 ± 9.8 (32.5 to 78.4) |
| BMI | 21.7 ± 3.4 (15 to 28.2) |
| Steinbrocker classification[ | |
| Stage | III (12), IV (38) |
| Functional class | I (3), II (23), III (22), IV (2) |
| DAS28-CRP score | |
| Preop. | 2.86 ± 0.76 |
| Latest follow-up | 2.52 ± 0.74 |
| Prednisolone dosage | |
| Preop. | 1.88 ± 2.6 |
| Latest follow-up | 1.67 ± 2.6 |
| Prednisolone usage | |
| Preop. | 48% (24 of 50) |
| Latest follow-up | 40% (20 of 50) |
| Methotrexate usage | 70% (35 of 50) |
| Biologics usage | |
| Preop. | 46% (23 of 50) |
| Latest follow-up | 52% (26 of 50) |
| Biologics used | Tocilizumab (14), infliximab (2), etanercept (1), adalimumab (2), golimumab (2), abatacept (5) |
| Previous surgery | Total (42 of 50), HHR (2), THA (14), TEA (13), TKA (33), TAA on contralateral side (6), cervical spine (4), lumbar spine (1), hindfoot (13), forefoot (8), wrist and hand (7) |
| Augmentation of tibia with hydroxyapatite | 94% (47 of 50) |
| Concomitant malleolar osteotomy | 40% (20 of 50) |
| Subtalar-talonavicular fusion | Ankylosing (16 [2 of 16, calcaneal osteotomy]), prior to TAA (13), simultaneous (9), none (12) |
| Lower limb surgery after TAA | Total (30 of 50), THA (2), TKA (7), TAA on contralateral side (8), hindfoot (2), forefoot (20) |
BMI = body mass index, HHR = humeral head replacement, THA = total hip arthroplasty, TEA = total elbow arthroplasty, TKA = total knee arthroplasty, TAA: total ankle arthroplasty.
The values are given as the mean and the standard deviation, with or without the range in parentheses.
Significantly different from preoperative score (p = 0.03).
JSSF Rheumatoid Arthritis (RA) Foot and Ankle Scale Scores*
| JSSF RA Foot and Ankle Scale Score | Preop. | Latest Follow-up | P Value |
| General pain (30 points) | 7.45 ± 5.7 | 28.9 ± 3.1 | <0.0001 |
| Deformity (25 points) | 11.5 ± 4.1 | 16.9 ± 4.1 | <0.0001 |
| Motion (15 points) | 3.35 ± 2.2 | 7.3 ± 3.3 | <0.0001 |
| Walking ability (20 points) | 5.44 ± 2.8 | 15.4 ± 5.0 | <0.0001 |
| Activities of daily living (10 points) | 1.33 ± 1.0 | 3.3 ± 1.7 | <0.0001 |
The values are given as the mean and the standard deviation.
Self-Administered Foot Evaluation Questionnaire (SAFE-Q) at Time of Latest Follow-up*
| SAFE-Q Score | Score at Latest Follow-up |
| Pain and pain-related (100 points) | 77.3 ± 15.9 |
| Physical functioning and daily living (100 points) | 51.3 ± 19.5 |
| Social functioning (100 points) | 51.7 ± 30.3 |
| Shoe-related (100 points) | 55.2 ± 25.7 |
| General health and well-being (100 points) | 65.9 ± 26.1 |
The values are given as the mean and the standard deviation.
JSSF Rheumatoid Arthritis (RA) Foot and Ankle Scale and SAFE-Q Scale Scores for Non-Biologic and Biologic Treatment Groups
| Clinical Outcomes Scales | Non-Biologic Treatment Group (N = 24) | Biologic Treatment Group (N = 26) | P Value |
| JSSF RA Foot and Ankle Scale score | |||
| Preop. | |||
| General pain (30 points) | 7.14 ± 5.61 | 7.69 ± 5.87 | NS |
| Deformity (25 points) | 10.6 ± 3.61 | 12.2 ± 4.44 | NS |
| Motion (15 points) | 3.38 ± 2.77 | 3.32 ± 1.63 | NS |
| Walking ability (20 points) | 6.19 ± 3.12 | 4.80 ± 2.27 | NS |
| Activities of daily living (10 points) | 1.38 ± 1.20 | 1.28 ± 0.84 | NS |
| Latest follow-up | |||
| General pain (30 points) | 29.0 ± 3.01 | 28.5 ± 3.26 | NS |
| Deformity (25 points) | 16.4 ± 4.30 | 17.4 ± 4.04 | NS |
| Motion (15 points) | 6.95 ± 4.08 | 7.60 ± 2.47 | NS |
| Walking ability (20 points) | 14.3 ± 17.7 | 16.4 ± 4.90 | NS |
| Activities of daily living (10 points) | 3.14 ± 1.80 | 3.44 ± 1.56 | NS |
| SAFE-Q Scale score at latest follow-up | |||
| Pain and pain-related (100 points) | 75.9 ± 17.7 | 78.4 ± 14.6 | NS |
| Physical functioning and daily living (100 points) | 49.1 ± 19.5 | 53.0 ± 19.8 | NS |
| Social functioning (100 points) | 38.7 ± 29.6 | 62.7 ± 27.0 | 0.0079 |
| Shoe-related (100 points) | 55.9 ± 26.0 | 54.6 ± 26.0 | NS |
| General health and well-being (100 points) | 66.3 ± 25.1 | 65.6 ± 27.4 | NS |
NS = not significant.
Comparison of Non-Biologic and Biologic Treatment Groups
| Non-Biologic Treatment Group (N = 24) | Biologic Treatment Group (N = 26) | P Value | |
| Age | 65.0 ± 7.2 | 63.0 ± 9.9 | NS |
| Duration of disease | 18.4 ± 9.2 | 20.1 ± 10.6 | NS |
| Duration of follow-up† | 6.9 ± 2.9 (3 to 14) | 7.2 ± 3.8 (3 to 14) | NS |
| Female:male ratio | 21:3 | 21:5 | NS |
| Height | 151.2 ± 7.8 (134 to 165) | 153.0 ± 8.8 (144 to 179) | NS |
| Weight | 47.9 ± 8.8 (32.5 to 69.1) | 52.5 ± 10.1 (36 to 78.4) | NS |
| BMI | 21.0 ± 3.9 (15 to 28.2) | 22.3 ± 2.8 (17 to 27.1) | NS |
| Steinbrocker classification[ | |||
| Stage | III (7), IV (17) | III (5), IV (21) | NS |
| Functional class | I (1), II (12), III (10), IV (1) | I (1), II (11), III (12), IV (2) | NS |
| Prednisolone | |||
| Dosage | 3.0 ± 2.9 | 0.5 ± 1.4 | 0.0003 |
| Rate of usage | 71% (17 of 24) | 12% (3 of 26) | 0.0001 |
| DAS28-CRP score | |||
| Preop. | 3.0 ± 0.9 | 2.72 ± 0.63 | NS |
| Latest follow-up | 2.83 ± 0.72 | 2.24 ± 0.66 | <0.01 |
| Methotrexate usage | 83% (20 of 24) | 58% (15 of 26) | NS |
| Angle C at latest follow-up | 88.7 ± 2.1 | 89.6 ± 1.3 | NS |
| Angle D at latest follow-up | 85.4 ± 2.3 | 85.9 ± 2.6 | NS |
| Angle E at latest follow-up | −0.01 ± 0.5 | 0.1 ± 1.1 | NS |
| Tibiocalcaneal angle | |||
| Preop. | 2.6 ± 8.7 | 5.6 ± 7.5 | NS |
| Latest follow-up | 3.2 ± 4.0 | 4.4 ± 3.1 | NS |
| Talar component sinking | 8% (2 of 24) | 23% (6 of 26) | NS |
| Focal radiolucent area | 13% (3 of 24) | 19% (5 of 26) | NS |
| Surgery in lower limb in history | |||
| Forefoot | 3 | 5 | — |
| Hindfoot | 6 | 7 | — |
| Total hip arthroplasty | 9 | 5 | — |
| Total knee arthroplasty | 19 | 14 | — |
| Surgery in lower limb after TAA | |||
| Forefoot | 8 | 12 | — |
| Hindfoot | 0 | 2 | — |
| Total hip arthroplasty | 1 | 1 | — |
| Total knee arthroplasty | 2 | 5 | — |
| TAA on contralateral side | 3 | 3 | — |
| Revision TAA required | 0% (0 of 24) | 8% (2 of 26) | NS |
| Additional calcaneal osteotomy | 0% (0 of 24) | 8% (2 of 26) | NS |
NS = not significant.
Evaluation performed with use of chi-square analysis.
Postoperative Issues and Radiographic Findings After TAA
| Delayed wound-healing | 10% (5 of 50) |
| Deep or periprosthetic infection | 0% (0 of 50) |
| Cellulitis around ankle joint | 2% (1 of 50) |
| Deep-vein thrombosis | 0% (0 of 50) |
| Revision TAA required | 4% (2 of 50) |
| Additional calcaneal osteotomy | 4% (2 of 50) |
| Intraoperative malleolar fracture | 14% (7 of 50) |
| Delayed union at site of malleolar osteotomy | 15% (3 of 20) |
| Nonunion at site of osteotomy | 0% (0 of 20) |
| Migration of tibial component | 0% (0 of 50) |
| Sinking of talar component | 16% (8 of 50) |
| Focal radiolucent area | 16% (8 of 50) |
Radiographic Angles
| Preop. | Latest Follow-up | P Value | |
| Angle C | 89.2 ± 1.8 | ||
| Angle D | 85.7 ± 2.4 | ||
| Angle E | −0.07 ± 0.9 | ||
| Tibiocalcaneal angle | 4.5 ± 8.5 | 3.6 ± 3.5 | 0.003 |
The values are given as the mean and the standard deviation.
Significant difference (p = 0.003). Statistical analysis was performed with use of the difference from 2°.
Relationships Between Revision TAA and Talar Component Sinking and Between Subtalar Joint Fusion and Talar Component Sinking
| Talar Component Sinking | Subtalar Joint Fusion | |||||
| Yes | No | P Value | Yes | No | P Value | |
| Revision TAA required | 25% (2 of 8) | 0% (0 of 42) | <0.001 | — | — | — |
| Talar component sinking | — | — | — | 21% (8 of 38) | 0% (0 of 12) | NS (0.08) |
Chi-square analysis. NS = not significant.